The Johnson & Johnson-backed Switzerland-based protein developer is looking to go public after raising almost $60m in equity funding.

Switzerland-based biotechnology company Molecular Partners filed for an initial public offering on Tuesday that could raise up to $134m.

Molecular is working on treatments based around protein therapeutics known as DARPins, for which it has developed clinical and preclinical product candidates and research programmes.

The company raised $44m from a 2009 series B round from Johnson & Johnson Development Corporation, the corporate venturing arm of pharmaceutical company Johnson & Johnson, Endeavour Vision, BB Biotech Ventures, Index Ventures and Essex Woodlands…